These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1973563)

  • 1. Preclinical studies with compound GYKI-22441, a new long-acting neuroleptic phenothiazine.
    Király I; Borsy J; Tapfer M; Losonczy S; Rásky K; Toldy L; Tóth I
    Acta Physiol Hung; 1990; 75 Suppl():171-2. PubMed ID: 1973563
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioimmunoassay for a new phenothiazine derivative and its application.
    Rásky K; Losonczy S; Pátfalusi M
    Acta Physiol Hung; 1992; 79(1):103-11. PubMed ID: 1363169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
    Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
    Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
    [No Abstract]   [Full Text] [Related]  

  • 4. Behavioral consequences of long-term treatment with neuroleptic drugs.
    Iversen SD; Howells RB; Hughes RP
    Adv Biochem Psychopharmacol; 1980; 24():305-13. PubMed ID: 6105782
    [No Abstract]   [Full Text] [Related]  

  • 5. Study of accumulation of fluphenazine enanthate and fluphenazine decanoate, long-acting neuroleptic drugs, after repeated administrations by means of their inhibitory effects on the discriminated avoidance response in rats.
    Kuribara H; Tadokoro S
    J Toxicol Sci; 1979 May; 4(2):87-98. PubMed ID: 501762
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of a single dose of some long-acting neuroleptics on the estrus cycle and the mammary gland of the rat].
    Lanza JP; Goude F; Lanza M
    C R Seances Soc Biol Fil; 1979; 173(4):797-806. PubMed ID: 43191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for evaluation of long acting neuroleptic drugs in animals.
    Kazdová E; Dlabac A; Metysová J
    Act Nerv Super (Praha); 1972; 14(2):126-7. PubMed ID: 5064759
    [No Abstract]   [Full Text] [Related]  

  • 8. Esters of 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazieneethanol and related compounds as long-acting antipsychotic agents. Synthesis of the 1-adamantoate, the first crystalline base.
    Yale HL
    J Med Chem; 1977 Feb; 20(2):302-4. PubMed ID: 13218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase inhibitors--are they potential neuroleptic drugs?
    Becker A; Grecksch G
    Behav Brain Res; 2008 Jan; 186(2):155-60. PubMed ID: 17854922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fluphenazine enanthate and fluphenazine decanoate on discriminated avoidance response and water drinking behavior in rats.
    Kuribara H; Tadokoro S
    Psychopharmacology (Berl); 1979 Sep; 65(1):1-6. PubMed ID: 116283
    [No Abstract]   [Full Text] [Related]  

  • 13. Antagonism of apomorphine induced climbing: is it a valid model for neuroleptic activity?
    Wallach MB; Hedley LR; Peterson KE; Schulz CH
    Proc West Pharmacol Soc; 1980; 23():93-8. PubMed ID: 6105667
    [No Abstract]   [Full Text] [Related]  

  • 14. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
    Ereshefsky L; Saklad SR; Jann MW; Davis CM; Richards A; Seidel DR
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):50-9. PubMed ID: 6143748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral and electroencephalographic effects of a depot type neuroleptic fluphenazine decanoate, in rats.
    Yamamoto T; Ueki S
    J Pharmacobiodyn; 1989 Nov; 12(11):681-92. PubMed ID: 2632765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacologic studies of a prolonged action neuroleptic: fluphenazine enanthate].
    Boissier JR; Simon P; Lwoff JM
    Med Pharmacol Exp Int J Exp Med; 1966; 14(5):435-42. PubMed ID: 6012744
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes.
    Merali Z; Toth G
    Pharmacol Biochem Behav; 1982 Jul; 17(1):25-30. PubMed ID: 7122665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the lack of a human metabolic isotope effect of a deuterium analog of fluphenazine.
    Hadad S; Hubbard JW; McKay G; Hawes EM; Shrikhande S; Midha KK
    Pharm Res; 1995 Sep; 12(9):1388-90. PubMed ID: 8570541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.